AccBio Conference Program | AIChE

Other Sites & Tools

Technical Groups

AccBio Conference Program

...

Sunday, March 1
3:15-5:30 Registration Check In
4:00-4:15 Conference Open (Chairs)
4:15-5:00

Keynote: Biologics Beyond Today's Markets: The Case for Innovation in Bioprocess R&D to Enable Global Access of Biologics- Stephen Hadley, Bill & Melinda Gates Foundation
5:00-5:45

Keynote: Will Change in the Pharmaceutical Industry also Change the Industry's Pecking Order?- Bernard Munos, InnoThink Center for Research in Biomedical Innovation
5:45-6:30 Rapid Fire Presentations
6:30-7:30 Opening Reception and Poster Session
   

Monday, March 2
8:00-12:00 Registration Check In
8:15-8:45 Breakfast
8:45-9:30

Keynote: Increasing need for responsiveness and flexibility in clinical and commercial bio-pharmaceutical supply chains- Prashant Yadav, University of Michigan
9:30-10:00 Conference Introduction (Chairs)
10:00-10:30  Break
10:30-12:00

Session 1: Speed
 
Session Chairs: Kevin Bailey, Regeneron and Rohini Deshpande, Amgen
10:30-11:00

Integrated Strategy to Enable Rapid Rapid Delivery of Material for IND Enabling Toxicology Studies- Scott Estes, Biogen Idec
11:00-11:30 Accelerated Drug Development Enabled by Velocimab® Technologies- Darya Burakov, Regeneron
11:30-12:00

Towards Making Biologic Drugs on Demand- Chris Love, MIT
12:00-1:30 Lunch
1:30-3:15
Session 1: Speed
1:30-2:00 Amgen's Next Generation Biomanufacturing Facility- Kimball Hall, Amgen
2:00-2:30

Development of a Device Platform to Speed Products to Clinic and Market- Ron Peeples, Pfizer
2:30-3:15 Speed Wrap-Up/Panel Discussion
3:15-3:45 Break
3:45-4:30 Rapid Fire Session
4:30-6:00 Poster Session and Reception
  Session Chairs: Louane Hann, Pfizer and Hubie Scoble, Genzyme
   

Tuesday, March 3
8:00-12:00 Registration Check In
8:15-8:45 Breakfast
8:45-10:15

Session 2: Cost
 
Session Chairs: Rohin Mhatre, Biogen Idec and Arup Roy, Lilly
8:45-9:15 Continuous vs. Batch Bioprocessing- Charlie Cooney, MIT
9:15-9:45 Does Pfizer Need a Low Cost Low Volume Manufacturing Option?- Jeff Salm, Pfizer
9:45-10:15  Improving Manufacturing Network Productivity: Overcoming the Downstream Bottlenecks- Lynn Conley, Biogen Idec
10:15-10:45 Break
10:45-12:30
Session 2: Cost
10:45-11:15 Rapid Process Development Enabled by Automated, Single Use High Throughput Technologies- Chris Kistler, Merck
11:15-11:45 Ultra Scale-Down (USD) Technologies for a Scaleable and Informed Biomanufacturing- Andrea Rayat, University College London
11:45-12:30 Cost Wrap-Up/Panel Discussion
12:30-2:00 Lunch
2:00-3:30

Session 3: Quality
 
Session Chairs: Jerry Cacia, Genentech, Bob Kiss, Genentech and Yuan Xu, Gilead
2:00-2:30 Beyond Numerical Tools:  Control Strategy Principles that Assure Product Quality Throughout Development- Meg Ruesch, Pfizer
2:30-3:00 Unlocking the Power of Analytics Support of QbD in Development- Hanne Bak, Regeneron
3:00-3:30 Studying and Controlling Product Quality Attributes in Biotherapeutics- Greg Flynn, Amgen
3:30-4:00 Break
4:00-6:15
Session 3: Quality
4:00-4:30 Understand & Control Product Quality Attributes in Cell Culture- Anli Ouyang, Lilly
4:30-5:00 Closing the Gap- Addressing Similarity Challenges of a Biotherapeutic With the Innovator Product- Gargi Seth, Intas
5:00-5:30 A Chinese Hamster Ovary Cell Host Cell Protein that Impacts PS-80 Degradation- Kelvin Lee, University of Delaware
5:30-6:15 Quality Wrap-Up/Panel Discussion
6:15-7:15 Poster Session
7:15-8:30 Dinner
   

Wednesday, March 4
8:00-9:00 Registration Check In
8:15-8:45 Breakfast
8:45-10:15

Session 4: Integration
 
Session Chairs: Brendan Hughes, Bristol Myers Squibb and Gene Schaefer, J&J
8:45-9:15 Faster to Patient Approach for Significant Benefit in Cost, Time, and Product Quality- Rohini Deshpande, Amgen
9:15-9:45 A Process Development Strategy Providing Flexibility While Balancing Cost and Speed without Sacrificing Quality- Martin Allen, Pfizer
9:45-10:15 Continuous Processing fro Pre-Clinical and Clinical Manufacturing: Balancing Speed, Cost and Quality- Jon Coffman, Boehringer Ingelheim
10:15-10:45 Break
10:45-1:00
Session 4: Integration
10:45-11:15 Henrik Andersen, Bristol Myers Squibb
11:15-11:45 Developing a Leading Open-Access Integrated Biologics Discovery, Development and Manufacturing Platform to Expedite Global Development- Weichang Zhou, WuXi
11:45-12:15 Scale-Down and Process Intensification: Two Key Opportunities for Integration and Cost Reduction- Gunter Jagschies, GE
12:15-1:00 Integration Wrap-Up/Panel Discussion and Conference Close

Sponsors

See All Sponsors

You may also be looking for...